



For Immediate Release:

Aegis Therapeutics Presents Overview of Recent Advances in Intranasal Drug Delivery of Peptide and Protein Therapeutics in PharmaVentures' Drug Delivery Companies Report, Spring/Summer 2005 Edition

San Diego, CA June 13, 2005 -- Improvements in intranasal drug delivery and in particular the development of novel, highly effective and non-irritating transmucosal absorption enhancement agents for proteins, peptides and non peptide macromolecule therapeutics are described in a just published article entitled: "Recent Developments in Intranasal Drug Delivery Technology are Creating New Vistas for Peptide and Protein Therapeutics", by Edward T. Maggio, PhD., CEO and President of Aegis, appearing in PharmaVentures' "Drug Delivery Companies Report - Spring/Summer 2005. The effects on creating new commercial and clinical opportunities for pharmaceutical and biopharmaceutical companies and more convenient and patient friendly therapeutic options across a broad spectrum of human diseases are also described.

Contact:

Ralph Barry,
Chief Business Officer/CFO
Aegis Therapeutics LLC
16870
West Bernardo Drive,
Suite 390
San Diego, CA 92127

Phone: 858-618-1400
Mobile: 858-967-6840
Facsimile: 858-618-1441

www.aegisthera.com

This information will be useful for companies with existing franchises in protein or peptide therapeutics or those seeking novel intranasal formulations of existing therapeutics for patent-life extension and product proliferation as an integral part of product life-cycle management. Information about this and other PharmaVentures reports and industry resources may be found at <http://www.pharmaventures.com/reports.html>.

About Aegis Therapeutics

Aegis Therapeutics Inc. is a specialty pharmaceutical company formed to commercialize advanced patented drug delivery technologies that enable the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics. Aegis' Intravail™ absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal, ocular, and other mucosal membrane administration routes, delivering potent peptide, protein, and large molecule drugs that can currently only be delivered by injection. Additional Intravail™ competitive advantages include rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier with no or minimal irritation, avoidance of gastric hydrolysis in the stomach and "first pass effect" elimination by the liver that can accompany oral administration, greater patient convenience and compliance, elimination of needlestick injuries and associated transmission of bloodborne pathogens, compatibility with current nasal delivery devices, ease of formulation and compatibility with routine homogeneous formulation and dispensing manufacturing processes for ease of scale-up and production.